Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis.

被引：12

作者：

Kurth T. ^{[1
]}

Hennekens C.H. ^{[1
]}

Buring J.E. ^{[1
]}

Gaziano J.M. ^{[1
]}

机构：

[1] Brigham and Women's Hospital, Division of Aging, 1620 Tremont Street, Boston, 02120, MA

来源：

Current Rheumatology Reports | 2004年 / 6卷 / 5期

关键词：

Aspirin; Ibuprofen; Celecoxib; Naproxen; Rofecoxib;

D O I：

10.1007/s11926-004-0009-0

中图分类号：

学科分类号：

摘要：

Aspirin, nonsteroidal antiinflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors are widely used in patients with rheumatoid arthritis. Aspirin has the largest and most persuasive body of randomized trial evidence to support its use in secondary prevention for cardiovascular disease (CVD) and primary prevention for myocardial infarction. There is, however, a possible deleterious interaction between aspirin and NSAIDs on CVD that requires further research. Aspirin, NSAIDs, and to a lesser extent COX-2 inhibitors are associated with increased gastrointestinal side effects and bleeding, alone and in combination. The more widespread and appropriate use of aspirin in patients with rheumatoid arthritis will avoid many premature deaths in secondary prevention for CVD and first myocardial infarctions in primary prevention.

引用

页码：351 / 356

页数：5

共 130 条

[1]

Williams A(2004)The role of aspirin in cardiovascular diseases--forgotten benefits Expert Opin Pharmacother 5 109- 115

[2]

Hennekens CH(2001)Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient Gastroenterology 120 594- 606

[3]

Laine L(2003)The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis Ann Intern Med 138 795- 806

[4]

Spiegel BM(1998)Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors Circulation 97 1095- 1102

[5]

Targownik L(2002)Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients Br Med J 324 71- 86

[6]

Dulai GS(2003)An update on aspirin in the primary prevention of cardiovascular disease Arch Intern Med 163 2006- 2010

[7]

Gralnek IM(2003)Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal Arthritis Rheum 48 12- 20

[8]

Hennekens CH(2001)Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 1809- 1817

[9]

Eidelman RS(2003)Effect of ibuprofen on cardioprotective effect of aspirin Lancet 361 573- 574

[10]

Hebert PR(2003)Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs Circulation 108 1191- 1195

← 1 2 3 4 5 6 7 8 9 10 →